GB9624456D0 - Assay method - Google Patents

Assay method

Info

Publication number
GB9624456D0
GB9624456D0 GBGB9624456.1A GB9624456A GB9624456D0 GB 9624456 D0 GB9624456 D0 GB 9624456D0 GB 9624456 A GB9624456 A GB 9624456A GB 9624456 D0 GB9624456 D0 GB 9624456D0
Authority
GB
United Kingdom
Prior art keywords
assay method
epitopes
esat
vaccines
provision
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
GBGB9624456.1A
Other languages
English (en)
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Oxford University Innovation Ltd
Original Assignee
Oxford University Innovation Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=10803428&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=GB9624456(D0) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Oxford University Innovation Ltd filed Critical Oxford University Innovation Ltd
Priority to GBGB9624456.1A priority Critical patent/GB9624456D0/en
Publication of GB9624456D0 publication Critical patent/GB9624456D0/en
Priority to EP97913336A priority patent/EP0941478B2/en
Priority to DK01109298T priority patent/DK1152012T3/da
Priority to JP52441098A priority patent/JP4094674B2/ja
Priority to DE69737956T priority patent/DE69737956T2/de
Priority to AT97913336T priority patent/ATE213068T1/de
Priority to DE69710360T priority patent/DE69710360T3/de
Priority to CA002272881A priority patent/CA2272881C/en
Priority to ES97913336T priority patent/ES2172773T5/es
Priority to PCT/GB1997/003222 priority patent/WO1998023960A1/en
Priority to AT01109298T priority patent/ATE368052T1/de
Priority to DK97913336T priority patent/DK0941478T4/da
Priority to EP01109298A priority patent/EP1152012B1/en
Priority to AU50632/98A priority patent/AU728357C/en
Priority to US09/308,725 priority patent/US7575870B1/en
Priority to US12/510,594 priority patent/US8617821B2/en
Priority to US14/090,221 priority patent/US9360480B2/en
Pending legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56966—Animal cells
    • G01N33/56972—White blood cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/35—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Mycobacteriaceae (F)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/543—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56905—Protozoa
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56983—Viruses
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56983—Viruses
    • G01N33/56988—HIV or HTLV
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56983—Viruses
    • G01N33/56994—Herpetoviridae, e.g. cytomegalovirus, Epstein-Barr virus
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6863—Cytokines, i.e. immune system proteins modifying a biological response such as cell growth proliferation or differentiation, e.g. TNF, CNF, GM-CSF, lymphotoxin, MIF or their receptors
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6863—Cytokines, i.e. immune system proteins modifying a biological response such as cell growth proliferation or differentiation, e.g. TNF, CNF, GM-CSF, lymphotoxin, MIF or their receptors
    • G01N33/6866—Interferon
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6878—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids in epitope analysis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Cell Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Virology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Pathology (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • AIDS & HIV (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Peptides Or Proteins (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Analysing Materials By The Use Of Radiation (AREA)
GBGB9624456.1A 1996-11-25 1996-11-25 Assay method Pending GB9624456D0 (en)

Priority Applications (17)

Application Number Priority Date Filing Date Title
GBGB9624456.1A GB9624456D0 (en) 1996-11-25 1996-11-25 Assay method
EP01109298A EP1152012B1 (en) 1996-11-25 1997-11-25 CD8 based vaccine against tuberculosis
AU50632/98A AU728357C (en) 1996-11-25 1997-11-25 Assay method for peptide specific T-cells
CA002272881A CA2272881C (en) 1996-11-25 1997-11-25 Assay method for peptide specific t-cells
AT01109298T ATE368052T1 (de) 1996-11-25 1997-11-25 Cd8 tuberkulose impfstoffe
JP52441098A JP4094674B2 (ja) 1996-11-25 1997-11-25 ペプチド特異的т細胞のアッセイ方法
DE69737956T DE69737956T2 (de) 1996-11-25 1997-11-25 CD8 Tuberkulose Impfstoffe
AT97913336T ATE213068T1 (de) 1996-11-25 1997-11-25 Testverfahren für peptidspezifische t-zellen
DE69710360T DE69710360T3 (de) 1996-11-25 1997-11-25 Testverfahren für peptidspezifische t-zellen
EP97913336A EP0941478B2 (en) 1996-11-25 1997-11-25 Assay method for peptide specific t-cells
ES97913336T ES2172773T5 (es) 1996-11-25 1997-11-25 Procedimiento de dosificado de linfocitos t especificos para un peptido.
PCT/GB1997/003222 WO1998023960A1 (en) 1996-11-25 1997-11-25 Assay method for peptide specific t-cells
DK01109298T DK1152012T3 (da) 1996-11-25 1997-11-25 Tuberkulosevacciner
DK97913336T DK0941478T4 (da) 1996-11-25 1997-11-25 Assaymetode for peptidspecifikke T-celler
US09/308,725 US7575870B1 (en) 1996-11-25 2000-01-13 Assay method for peptide specific T-cells
US12/510,594 US8617821B2 (en) 1996-11-25 2009-07-28 Assay method for peptide specific T-cells
US14/090,221 US9360480B2 (en) 1996-11-25 2013-11-26 Assay method for peptide specific T-cells

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB9624456.1A GB9624456D0 (en) 1996-11-25 1996-11-25 Assay method

Publications (1)

Publication Number Publication Date
GB9624456D0 true GB9624456D0 (en) 1997-01-15

Family

ID=10803428

Family Applications (1)

Application Number Title Priority Date Filing Date
GBGB9624456.1A Pending GB9624456D0 (en) 1996-11-25 1996-11-25 Assay method

Country Status (11)

Country Link
US (3) US7575870B1 (https=)
EP (2) EP1152012B1 (https=)
JP (1) JP4094674B2 (https=)
AT (2) ATE213068T1 (https=)
AU (1) AU728357C (https=)
CA (1) CA2272881C (https=)
DE (2) DE69710360T3 (https=)
DK (2) DK0941478T4 (https=)
ES (1) ES2172773T5 (https=)
GB (1) GB9624456D0 (https=)
WO (1) WO1998023960A1 (https=)

Families Citing this family (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9624456D0 (en) * 1996-11-25 1997-01-15 Isis Innovation Assay method
DK1144447T3 (da) * 1998-11-04 2010-02-08 Isis Innovation Dianostisk tuberkulosetest
US20020131976A1 (en) 1998-12-23 2002-09-19 Ajit Lalvani Tuberculosis vaccine
GB9923306D0 (en) 1999-10-01 1999-12-08 Isis Innovation Diagnostic and therapeutic epitope, and transgenic plant
GB0006692D0 (en) * 2000-03-20 2000-05-10 Glaxo Group Ltd Epitopes
US20030198941A1 (en) * 2000-04-12 2003-10-23 Watkins David I. Method for making an HIV vaccine
NZ526807A (en) 2001-01-08 2005-03-24 Isis Innovation Assay to determine efficacy of treatment for mycobacterial infection
DE10125730A1 (de) * 2001-05-17 2002-11-21 A I D Autoimmun Diagnostika Gm Verfahren zum Nachweis von Erregern und durch diese induzierten zellulär produzierten Stoffen im lebenden Organismus
GB0212885D0 (en) 2002-06-05 2002-07-17 Isis Innovation Therapeutic epitopes and uses thereof
CA2536735C (en) * 2003-09-05 2013-01-22 Genencor International, Inc. Methods for determining cd8+ t-cell epitopes
ITRM20040091A1 (it) * 2004-02-19 2004-05-19 Istituto Naz Per Le Malattie Test immunologico rapido per la diagnosi ed il monitoraggio dell'infezione tubercolare.
US10105437B2 (en) 2004-04-28 2018-10-23 Btg International Limited Epitopes related to coeliac disease
AU2005237287B2 (en) 2004-04-28 2011-08-11 Btg International Limited Epitopes related to coeliac disease
EP2226332A1 (en) 2004-06-17 2010-09-08 Beckman Coulter, Inc. Mycobacterium tuberculosis epitopes and methods of use thereof
GB0605474D0 (en) * 2006-03-17 2006-04-26 Isis Innovation Clinical correlates
GB0619853D0 (en) 2006-10-06 2006-11-15 Oxford Immunotec Ltd Preparation method
DE102007052517A1 (de) 2007-10-29 2009-04-30 Autoimmun Diagnostika Gmbh ELISPOT-Verfahren mit zwei Filtersystemen
GB2455108A (en) * 2007-11-28 2009-06-03 Circassia Ltd T-Cell dependent method for detecting non-allergic or intrinsic disorders
JP2012503206A (ja) 2008-09-22 2012-02-02 オレゴン ヘルス アンド サイエンス ユニバーシティ Ｍｙｃｏｂａｃｔｅｒｉｕｍｔｕｂｅｒｃｕｌｏｓｉｓ感染を検出するための方法
GB0906215D0 (en) 2009-04-09 2009-05-20 Lalvani Ajit Diagnostic test
CN102713629B (zh) 2009-11-20 2016-02-24 俄勒冈健康科学大学 用于检测结核分枝杆菌感染的方法
IT1403092B1 (it) 2010-12-01 2013-10-04 Univ Degli Studi Modena E Reggio Emilia Metodo per la diagnosi e/o il monitoraggio della mucormicosi.
WO2012103315A2 (en) 2011-01-27 2012-08-02 Osa Holdings, Inc. Apparatus and methods for treatment of obstructive sleep apnea utilizing cryolysis of adipose tissues
FR2983213B1 (fr) 2011-11-30 2015-03-06 Commissariat Energie Atomique Procede de mesure en temps reel des secretions individuelles d'une cellule
WO2013093512A2 (en) * 2011-12-23 2013-06-27 Retroscreen Virology Ltd Vaccine - screening method
GB201122297D0 (en) 2011-12-23 2012-02-01 Retroscreen Virology Ltd Vaccine - screening method
US9678071B2 (en) 2012-01-12 2017-06-13 Mayo Foundation For Medical Education And Research Detecting latent tuberculosis infections
WO2013139972A1 (en) * 2012-03-23 2013-09-26 Laboratorios Del Dr. Esteve, S.A. Method for monitoring hiv specific t cell responses
US10401360B2 (en) 2013-04-29 2019-09-03 Mayo Foundation For Medical Education And Research Flow cytometry assay methods
AU2015249592A1 (en) 2014-04-24 2016-12-15 Immusant, Inc. Use of Interleukin-2 for diagnosis of Celiac disease
EP3200736B8 (en) 2014-10-01 2020-06-17 CryOSA, Inc. Apparatus for treatment of obstructive sleep apnea utilizing cryolysis of adipose tissues
AU2015349728A1 (en) 2014-11-21 2017-07-13 Immusant, Inc. Peptides for use in treatment and diagnosis of type 1 diabetes
FR3033333A1 (fr) 2015-03-06 2016-09-09 Commissariat Energie Atomique Procede et dispositif pour detecter en temps reel un compose secrete et la cible secretrice ainsi que leurs utilisations
CN110073215B (zh) 2016-09-22 2024-04-30 佩斯诊断公司 结核分枝杆菌蛋白诊断测定和结核病检测和诊断装置
US10245320B2 (en) 2016-09-30 2019-04-02 Enzo Biochem, Inc. Immunomodulatory pharmaceutical compositions and methods of use thereof
US10684275B2 (en) 2016-12-14 2020-06-16 Becton, Dickinson And Company Methods and compositions for obtaining a tuberculosis assessment in a subject
WO2019018607A1 (en) 2017-07-20 2019-01-24 Enzo Biochem, Inc. IMMUNOMODULATORY COMPOSITIONS AND METHODS OF USE THEREOF
EP3905976A4 (en) 2018-12-31 2022-09-21 CryOSA, Inc. SYSTEMS AND METHODS FOR TREATMENT OF OBSTRUCTIVE SLEEP APNEA
KR102182555B1 (ko) * 2019-03-14 2020-11-24 한국과학기술연구원 T 세포 면역 반응 활성화를 위한 암 치료용 암항원 발굴 플랫폼
EP3976764B1 (en) 2019-05-30 2025-07-23 Viti, Inc. Methods for detecting a mycobacterium tuberculosis infection
US12551259B2 (en) 2020-02-19 2026-02-17 Cryosa, Inc. Systems and methods for treatment of obstructive sleep apnea
CN111856020B (zh) * 2020-06-19 2022-09-27 南方医科大学南方医院 乙型肝炎病毒（hbv）特异性t细胞检测方法及其应用
EP4456841A4 (en) 2021-12-30 2025-12-24 Cryosa Inc SYSTEMS AND METHODS FOR THE TREATMENT OF OBSTRUCTIVE SLEEP APNEA

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1299099C (en) 1986-03-06 1992-04-21 Paul Richard Wood In vitro assay for detecting cell-mediated immune responses
US5955077A (en) 1993-07-02 1999-09-21 Statens Seruminstitut Tuberculosis vaccine
DK79893D0 (da) 1993-07-02 1993-07-02 Statens Seruminstitut New vaccine
US20020136733A1 (en) 1994-03-31 2002-09-26 Hill Adrian Vivian Sinton Malaria peptides
AU6280596A (en) * 1995-06-15 1997-01-15 University Of Victoria Innovation And Development Corporation Mycobacterium tuberculosis dna sequences encoding immunostimlatory peptides
DE19525784A1 (de) 1995-07-14 1997-01-16 Boehringer Mannheim Gmbh Autoreaktive Peptide aus der humanen Glutamin-Decarboxylase (GAD)
US6410252B1 (en) 1995-12-22 2002-06-25 Case Western Reserve University Methods for measuring T cell cytokines
US5939281A (en) 1996-09-16 1999-08-17 Case Western Reserve University Detecting alloreactivity
GB9624456D0 (en) 1996-11-25 1997-01-15 Isis Innovation Assay method
DK1144447T3 (da) * 1998-11-04 2010-02-08 Isis Innovation Dianostisk tuberkulosetest
US20020131976A1 (en) 1998-12-23 2002-09-19 Ajit Lalvani Tuberculosis vaccine
NZ526807A (en) 2001-01-08 2005-03-24 Isis Innovation Assay to determine efficacy of treatment for mycobacterial infection
GB0215710D0 (en) * 2002-07-05 2002-08-14 Isis Innovation Diagnostic method

Also Published As

Publication number Publication date
US7575870B1 (en) 2009-08-18
CA2272881C (en) 2007-10-09
DE69737956D1 (de) 2007-09-06
US20100203568A1 (en) 2010-08-12
JP2001505568A (ja) 2001-04-24
DK0941478T4 (da) 2007-10-08
DK1152012T3 (da) 2007-11-26
AU5063298A (en) 1998-06-22
AU728357C (en) 2001-11-01
US9360480B2 (en) 2016-06-07
ES2172773T3 (es) 2002-10-01
ATE213068T1 (de) 2002-02-15
ATE368052T1 (de) 2007-08-15
EP1152012B1 (en) 2007-07-25
DE69737956T2 (de) 2008-04-17
WO1998023960A1 (en) 1998-06-04
DK0941478T3 (da) 2002-07-01
AU728357B2 (en) 2001-01-04
ES2172773T5 (es) 2008-01-16
DE69710360T3 (de) 2008-01-17
EP0941478B2 (en) 2007-06-06
DE69710360T2 (de) 2002-11-14
DE69710360D1 (de) 2002-03-21
US20140087399A1 (en) 2014-03-27
JP4094674B2 (ja) 2008-06-04
CA2272881A1 (en) 1998-06-04
EP1152012A1 (en) 2001-11-07
EP0941478A1 (en) 1999-09-15
EP0941478B1 (en) 2002-02-06
US8617821B2 (en) 2013-12-31

Similar Documents

Publication Publication Date Title
GB9624456D0 (en) Assay method
SG49008A1 (en) Hla-a2.1 binding peptides and their uses
IL106610A0 (en) Hla binding peptides and their uses
HUP0101521A3 (en) Fusion proteins of mycobacterium tuberculosis antigens and their uses
EP0907370A4 (en) HLA-A2.1 BINDING PEPTIDES AND USES THEREOF
NZ301290A (en) Mycobacterial proteins, micro-organisms producing same and vaccines thereof
EP1189624A4 (en) Hla binding peptides and their uses
NZ335485A (en) Isolated nucleic acid molecule encoding cancer associated antigen, the antigen itself, and uses thereof
AU2001298049A8 (en) Hla class i and ii binding peptides and their uses
ATE87655T1 (de) Markierer der t-zelle aktivierung.
SG52342A1 (en) T cell antigen receptor v region protein and methos of preparation thereof
GB9409985D0 (en) Vaccine against mycobacterial infections
AU4577899A (en) Hla binding peptides and their uses
ES2308850T3 (es) Anticuerpos para antigenos de celulas de langerhans de mamiferos y sus usos.
BR9407357A (pt) Novos tripeptideos utilizáveis em terapia cns e imune
EP0317279A3 (en) Peptides for use in the purification of factor viii
CA2140091A1 (en) Peptides and antisera for detecting human cyclooxygenase-1 and cyclooxygenase-2
EP1026245A4 (en) ANTIGENIC PROTEIN AND THE NUCLEIC ACID CODING THEREOF
WO1997039020A3 (en) Antigenic sequences of a sperm protein and immunocontraceptive methods
AU7732894A (en) Graves' ophthalmopathy associated antibodies, graves' ophthalmopathy orbital antigen, and methods of use thereof
ZA9710584B (en) Peptides antibodies vaccines and uses thereof